Cargando…

Kinetics of antibody responses dictate COVID-19 outcome

Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucas, Carolina, Klein, Jon, Sundaram, Maria, Liu, Feimei, Wong, Patrick, Silva, Julio, Mao, Tianyang, Oh, Ji Eun, Tokuyama, Maria, Lu, Peiwen, Venkataraman, Arvind, Park, Annsea, Israelow, Benjamin, Wyllie, Anne L., Vogels, Chantal B. F., Muenker, M. Catherine, Casanovas-Massana, Arnau, Schulz, Wade L., Zell, Joseph, Campbell, Melissa, Fournier, John B., Grubaugh, Nathan D., Farhadian, Shelli, Wisnewski, Adam V., Cruz, Charles Dela, Omer, Saad, Ko, Albert I., Ring, Aaron, Iwasaki, Akiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781347/
https://www.ncbi.nlm.nih.gov/pubmed/33398304
http://dx.doi.org/10.1101/2020.12.18.20248331
_version_ 1783631659193597952
author Lucas, Carolina
Klein, Jon
Sundaram, Maria
Liu, Feimei
Wong, Patrick
Silva, Julio
Mao, Tianyang
Oh, Ji Eun
Tokuyama, Maria
Lu, Peiwen
Venkataraman, Arvind
Park, Annsea
Israelow, Benjamin
Wyllie, Anne L.
Vogels, Chantal B. F.
Muenker, M. Catherine
Casanovas-Massana, Arnau
Schulz, Wade L.
Zell, Joseph
Campbell, Melissa
Fournier, John B.
Grubaugh, Nathan D.
Farhadian, Shelli
Wisnewski, Adam V.
Cruz, Charles Dela
Omer, Saad
Ko, Albert I.
Ring, Aaron
Iwasaki, Akiko
author_facet Lucas, Carolina
Klein, Jon
Sundaram, Maria
Liu, Feimei
Wong, Patrick
Silva, Julio
Mao, Tianyang
Oh, Ji Eun
Tokuyama, Maria
Lu, Peiwen
Venkataraman, Arvind
Park, Annsea
Israelow, Benjamin
Wyllie, Anne L.
Vogels, Chantal B. F.
Muenker, M. Catherine
Casanovas-Massana, Arnau
Schulz, Wade L.
Zell, Joseph
Campbell, Melissa
Fournier, John B.
Grubaugh, Nathan D.
Farhadian, Shelli
Wisnewski, Adam V.
Cruz, Charles Dela
Omer, Saad
Ko, Albert I.
Ring, Aaron
Iwasaki, Akiko
author_sort Lucas, Carolina
collection PubMed
description Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization and clinical parameters associated with worse clinical progression. While high anti-S IgG levels correlated with worse disease severity, such correlation was time-dependent. Deceased patients did not have higher overall humoral response than live discharged patients. However, they mounted a robust, yet delayed response, measured by anti-S, anti-RBD IgG, and neutralizing antibody (NAb) levels, compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, while sera from 89% of patients displayed some neutralization capacity during their disease course, NAb generation prior to 14 days of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levels per se, but rather with the delayed kinetics of NAb production.
format Online
Article
Text
id pubmed-7781347
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-77813472021-01-05 Kinetics of antibody responses dictate COVID-19 outcome Lucas, Carolina Klein, Jon Sundaram, Maria Liu, Feimei Wong, Patrick Silva, Julio Mao, Tianyang Oh, Ji Eun Tokuyama, Maria Lu, Peiwen Venkataraman, Arvind Park, Annsea Israelow, Benjamin Wyllie, Anne L. Vogels, Chantal B. F. Muenker, M. Catherine Casanovas-Massana, Arnau Schulz, Wade L. Zell, Joseph Campbell, Melissa Fournier, John B. Grubaugh, Nathan D. Farhadian, Shelli Wisnewski, Adam V. Cruz, Charles Dela Omer, Saad Ko, Albert I. Ring, Aaron Iwasaki, Akiko medRxiv Article Recent studies have provided insights into innate and adaptive immune dynamics in coronavirus disease 2019 (COVID-19). Yet, the exact feature of antibody responses that governs COVID-19 disease outcomes remain unclear. Here, we analysed humoral immune responses in 209 asymptomatic, mild, moderate and severe COVID-19 patients over time to probe the nature of antibody responses in disease severity and mortality. We observed a correlation between anti-Spike (S) IgG levels, length of hospitalization and clinical parameters associated with worse clinical progression. While high anti-S IgG levels correlated with worse disease severity, such correlation was time-dependent. Deceased patients did not have higher overall humoral response than live discharged patients. However, they mounted a robust, yet delayed response, measured by anti-S, anti-RBD IgG, and neutralizing antibody (NAb) levels, compared to survivors. Delayed seroconversion kinetics correlated with impaired viral control in deceased patients. Finally, while sera from 89% of patients displayed some neutralization capacity during their disease course, NAb generation prior to 14 days of disease onset emerged as a key factor for recovery. These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levels per se, but rather with the delayed kinetics of NAb production. Cold Spring Harbor Laboratory 2020-12-22 /pmc/articles/PMC7781347/ /pubmed/33398304 http://dx.doi.org/10.1101/2020.12.18.20248331 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Lucas, Carolina
Klein, Jon
Sundaram, Maria
Liu, Feimei
Wong, Patrick
Silva, Julio
Mao, Tianyang
Oh, Ji Eun
Tokuyama, Maria
Lu, Peiwen
Venkataraman, Arvind
Park, Annsea
Israelow, Benjamin
Wyllie, Anne L.
Vogels, Chantal B. F.
Muenker, M. Catherine
Casanovas-Massana, Arnau
Schulz, Wade L.
Zell, Joseph
Campbell, Melissa
Fournier, John B.
Grubaugh, Nathan D.
Farhadian, Shelli
Wisnewski, Adam V.
Cruz, Charles Dela
Omer, Saad
Ko, Albert I.
Ring, Aaron
Iwasaki, Akiko
Kinetics of antibody responses dictate COVID-19 outcome
title Kinetics of antibody responses dictate COVID-19 outcome
title_full Kinetics of antibody responses dictate COVID-19 outcome
title_fullStr Kinetics of antibody responses dictate COVID-19 outcome
title_full_unstemmed Kinetics of antibody responses dictate COVID-19 outcome
title_short Kinetics of antibody responses dictate COVID-19 outcome
title_sort kinetics of antibody responses dictate covid-19 outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781347/
https://www.ncbi.nlm.nih.gov/pubmed/33398304
http://dx.doi.org/10.1101/2020.12.18.20248331
work_keys_str_mv AT lucascarolina kineticsofantibodyresponsesdictatecovid19outcome
AT kleinjon kineticsofantibodyresponsesdictatecovid19outcome
AT sundarammaria kineticsofantibodyresponsesdictatecovid19outcome
AT liufeimei kineticsofantibodyresponsesdictatecovid19outcome
AT wongpatrick kineticsofantibodyresponsesdictatecovid19outcome
AT silvajulio kineticsofantibodyresponsesdictatecovid19outcome
AT maotianyang kineticsofantibodyresponsesdictatecovid19outcome
AT ohjieun kineticsofantibodyresponsesdictatecovid19outcome
AT tokuyamamaria kineticsofantibodyresponsesdictatecovid19outcome
AT lupeiwen kineticsofantibodyresponsesdictatecovid19outcome
AT venkataramanarvind kineticsofantibodyresponsesdictatecovid19outcome
AT parkannsea kineticsofantibodyresponsesdictatecovid19outcome
AT israelowbenjamin kineticsofantibodyresponsesdictatecovid19outcome
AT wyllieannel kineticsofantibodyresponsesdictatecovid19outcome
AT vogelschantalbf kineticsofantibodyresponsesdictatecovid19outcome
AT muenkermcatherine kineticsofantibodyresponsesdictatecovid19outcome
AT casanovasmassanaarnau kineticsofantibodyresponsesdictatecovid19outcome
AT schulzwadel kineticsofantibodyresponsesdictatecovid19outcome
AT zelljoseph kineticsofantibodyresponsesdictatecovid19outcome
AT campbellmelissa kineticsofantibodyresponsesdictatecovid19outcome
AT fournierjohnb kineticsofantibodyresponsesdictatecovid19outcome
AT kineticsofantibodyresponsesdictatecovid19outcome
AT grubaughnathand kineticsofantibodyresponsesdictatecovid19outcome
AT farhadianshelli kineticsofantibodyresponsesdictatecovid19outcome
AT wisnewskiadamv kineticsofantibodyresponsesdictatecovid19outcome
AT cruzcharlesdela kineticsofantibodyresponsesdictatecovid19outcome
AT omersaad kineticsofantibodyresponsesdictatecovid19outcome
AT koalberti kineticsofantibodyresponsesdictatecovid19outcome
AT ringaaron kineticsofantibodyresponsesdictatecovid19outcome
AT iwasakiakiko kineticsofantibodyresponsesdictatecovid19outcome